Common Lactation Drug Linked to Sharply Lower Breast Cancer Risk

A drug that new mothers sometimes take for a simple reason, to dry up breast milk they no longer need, may come with an unexpected second payoff: sharply lower odds of breast cancer in the years after childbirth. In a combined analysis of two large European studies, women who received cabergoline shortly after giving birth were about 69% less likely to develop breast cancer than women who didn’t.

Breast cancer that shows up in the years right after pregnancy tends to be more aggressive and harder to treat than cancer diagnosed at other times. Scientists have long known that having a baby early offers long-term protection against breast cancer, but the months right after childbirth actually bring a temporary spike in risk, one that hits hardest for women who had their first child later in life or who carry BRCA1 gene mutations. Until now, no specific method has protected those women during that dangerous stretch.

Researchers from institutions in Spain, Canada, Norway, the United Kingdom, Singapore and the United States, reporting in the journal Cancer Discovery, tested whether cabergoline, already approved to stop lactation, could close that gap. In mice bred to carry a high-risk breast cancer mutation, a single dose of the drug given right after weaning sharply delayed and reduced tumors, a clue that helped explain the pattern researchers later found in women.

How a Single Dose of Cabergoline Cut Breast Cancer in Mice

To test the idea, researchers used mice bred without working copies of two genes that normally guard against cancer: BRCA1 and a second gene called Trp53. Female mice that went through two full rounds of pregnancy, breastfeeding, and the natural recovery period afterward developed tumors later, and less often, than mice that never had pups at all. Tumors appeared around day 224 in mice that had given birth, compared with day 175 in mice that hadn’t. Only 59% of the mothers developed tumors, versus nearly 89% of the childless mice.

Then the team gave a single dose of cabergoline to another group of mother mice right when breastfeeding ended. Tumors took even longer to appear, around 259 days, and only about 28% of treated mice developed tumors. Giving the same drug to mice that had never been pregnant did almost nothing to protect them, which told researchers the benefit was tied specifically to the recovery window after breastfeeding, not some general cancer-fighting effect.

So what’s actually happening inside the breast tissue during that window? After a mother stops nursing, the breast naturally shrinks back down, clearing out the milk-producing cells it no longer needs. In mice carrying the cancer-linked gene mutations, that cleanup process slowed and left behind riskier tissue, including cells with two nuclei instead of one, which are especially prone to becoming cancerous when their normal damage-control systems are broken. Cabergoline noticeably sped up that cleanup: treated breast tissue shrank faster, had fewer risky double-nuclei cells, and showed less overall tissue growth two months later.

Cabergoline also seemed to help the immune system. Breast tissue from the high-risk mice showed signs that T cells, the immune cells that normally hunt down and destroy abnormal cells, had become worn out and less effective. Cabergoline appeared to reverse that pattern. Treated tissue had more active, cancer-fighting T cells and fewer that showed signs of exhaustion. Researchers believe the combination, healthier tissue plus a stronger immune response, helps explain why treated mice developed far fewer tumors.

What Cabergoline Means for Breast Cancer in Real Women

To see whether any of this held up outside the lab, researchers examined medical records from two different European populations. The first came from a primary care database in Catalonia, Spain, covering more than 14,800 women who had their first child at age 30 or older. Of those, 780 had received cabergoline within a month of giving birth. Over an average of eight years of follow-up, only 2 of those 780 women developed breast cancer, compared to 132 cases among the more than 14,000 women who hadn’t taken the drug. After accounting for other risk factors like age, smoking, family history and income, women who’d taken cabergoline still showed roughly a 75% lower risk of developing breast cancer.

A second analysis using the same Spanish database, this time looking at all women within ten years of their first pregnancy regardless of age, told a similar story: 2 cancer cases among 1,604 treated women, compared to 125 cases among nearly 26,000 untreated women.

To make sure the pattern wasn’t unique to one country, researchers checked it against a nationwide registry in Norway covering more than 690,000 women. The results pointed in the same protective direction, though the small number of cancer cases there, 2 among treated women compared to 899 among untreated women, meant the finding didn’t clear the usual bar scientists use to call a result reliable on its own. When the team combined the data from both countries, the pooled analysis showed an estimated 69% reduction in breast cancer risk linked to cabergoline use after childbirth.

These human studies come with real caveats. Both looked back at existing medical records rather than randomly assigning some women to take the drug and others not to, so they can reveal patterns without proving the drug directly caused the lower cancer rates. The number of actual cancer cases among treated women was small in every dataset, which makes the percentages look large but also means a handful of additional cases either way could shift the numbers quite a bit. The researchers describe the human findings as evidence to motivate further study, not final proof.

Still, the picture lines up across species and countries. In mice, a single, well-timed dose changed breast tissue biology in ways that reduced tumor formation. In two separate groups of women, the same drug given at the same life stage lined up with far fewer breast cancer diagnoses. As the authors put it in their paper, the postpartum period is “an under-addressed window of elevated breast cancer risk, particularly in genetically susceptible women.”

Beyond the risk reduction, cabergoline’s appeal lies in its simplicity. Current breast cancer prevention drugs, like tamoxifen, work well for some women but come with real downsides, including a higher risk of blood clots and uterine cancer, and roughly 40% of women stop taking them before finishing the recommended five-year course. Cabergoline, by contrast, is already given as a short, single-dose treatment to stop lactation, and it carries an established tolerability record from that long-standing use. If future clinical trials bear this out, a decades-old medication already sitting in hospital maternity wards could become a simple way to protect the women who need it most, especially those carrying BRCA1 mutations who currently have no targeted option during the riskiest stretch of their lives.

Disclaimer: This article describes early research. The strongest results come from experiments in genetically engineered mice, and the human findings come from observational studies that can show an association between cabergoline use and lower breast cancer rates but cannot prove the drug caused that reduction. Cabergoline is not approved or proven to prevent breast cancer, and no one should start, stop, or change any medication based on this study. Anyone with questions about breast cancer risk or prevention should talk with a qualified healthcare provider.